Close Menu
    GCC TabloidGCC Tabloid
    • Automotive

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      Japan new car sales rise 1.8% in first half of 2026

      July 2, 2026

      Porsche reveals bespoke 911 GT3 RS in Macadamiametallic

      May 18, 2026

      Mercedes-Benz unveils electric C-Class in Seoul

      April 21, 2026

      2027 Mercedes-Benz S-Class adds DIGITAL LIGHT micro-LEDs

      January 30, 2026
    • Business

      AfDB backs Morocco reforms and climate resilience with €434.4m

      November 14, 2026

      DP World partner ATI wins 25-year Manila port renewal

      November 13, 2026

      ADB flags $264 billion yearly ASEAN infrastructure gap

      November 12, 2026

      Amin Adam questions how Ghana will fund $10bn New Economy

      November 11, 2026

      Samsung Electronics cash assets hit record 214.8 trillion won

      November 9, 2026
    • Entertainment

      Sony confirms God of War trilogy remake and PS5 prequel

      February 13, 2026

      Apple Arcade adds Jeopardy and NFL games in September update

      August 19, 2025

      Moscow hosts historic 47th international festival

      April 19, 2025

      Legal action against ‘Ketamine Queen,’ doctors in Perry overdose

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024
    • Health

      Yellow fever kills 18 across nine African nations, WHO says

      November 7, 2026

      Dengue kills 173 in October as Bangladesh toll climbs to 418

      November 2, 2026

      Ebola deaths in DR Congo reach 5,340, fatality rate at 51.6%

      November 2, 2026

      Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

      October 28, 2026

      Malaria kills 22 in Namibia’s Zambezi Region as cases rise

      October 26, 2026
    • Lifestyle

      Adidas unveils Treadflow, a treadmill shoe innovation

      August 24, 2025

      U.S. Polo Assn.’s fall-winter 2024 line inspired by Salt Lake City

      September 20, 2024

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023
    • Luxury

      Global luxury market contracts for first time since Great Recession

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      Sheikh Mohamed receives Arab League chief Nabil Fahmy

      November 14, 2026

      Three nations launch carbon crediting initiative at COP31

      November 13, 2026

      Nigeria and EU seal readmission deal after decade of talks

      November 12, 2026

      Modi and Zelenskyy discuss peace efforts and bilateral ties

      November 11, 2026

      UAE and Tanzania explore wider economic and trade cooperation

      November 9, 2026
    • Sports

      Africa hosts first Olympic event as Dakar 2026 YOG begins

      October 30, 2026

      Messi ends Argentina career with 207 caps and 125 goals

      September 1, 2026

      FIA President meets with Hungarian PM and Czech President

      July 28, 2026

      Portugal fall to Spain as Ronaldo legacy closes

      July 7, 2026

      Brazil exits World Cup after Norway Round of 16 victory

      July 6, 2026
    • Technology

      MEAPMP Launches: Revamped Independent Ad-Tech & Premium Media Buying Across MEA

      November 3, 2026

      Sam Altman calls UAE most forward-looking country on AI

      November 3, 2026

      Apple iPhone Duo sets a new benchmark for foldable design

      November 2, 2026

      Apple brings Touch and PROLED XDR display to MacBook Pro

      October 29, 2026

      Integrated Identity Enters Global Top 0.1% with Rare 100/100 Google PageSpeed

      October 29, 2026
    • Travel

      Türkiye aims to rank sixth in global tourism revenue

      October 21, 2026

      Air Arabia launches Sharjah flights to Amman City Airport

      October 9, 2026

      Air Arabia resumes daily Ras Al Khaimah Kozhikode service

      October 7, 2026

      flydubai showcases growing Syria network with daily flights

      September 29, 2026

      Emirates enters winter season with strong booking momentum

      September 15, 2026
    GCC TabloidGCC Tabloid
    Home » African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
    PR Newswire

    African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

    August 27, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    CEPI backs Minapharm’s Bundibugyo ebolavirus vaccine candidate, based on ProBioGen’s proprietary MVA-CR19 platform

    OSLO, Norway, CAIRO and BERLIN, Aug. 27, 2026 /PRNewswire/ — Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

    CEPI backs Minapharm's Bundibugyo ebolavirus vaccine candidate, based on ProBioGen's proprietary MVA-CR19 platform

    Minapharm’s Bundibugyo vaccine is designed by ProBioGen, a Berlin-based specialist within Minapharm Group, based on their proprietary modified vaccinia Ankara (MVA) vaccine platform, MVA-CR19. A similar technology underpins a licensed vaccine against smallpox and mpox, and has elicited long-term immunity in a vaccine targeting the related Zaire ebolavirus.

    CEPI’s funding will advance the Bundibugyo vaccine candidate through preclinical development and into an early-stage clinical trial to assess the immunogenicity and safety of the vaccine candidate. The study in humans, known as a Phase 1 trial, is expected to take place in Africa.

    Minapharm’s investigational vaccine becomes the fifth Bundibugyo-specific virus vaccine candidate supported by CEPI in response to the escalating epidemic. It joins a portfolio of promising CEPI-backed candidates* built on different vaccine technologies to maximise the likelihood of developing a safe and effective shot that could help bring this devastating crisis under control.

    It is the only Bundibugyo vaccine candidate CEPI is funding that is designed to induce both B- and T-cell responses for comprehensive and long-lasting immunity.

    “CEPI’s funding to Minapharm harnesses the growing strength of African-led innovation to help confront this increasingly severe outbreak and prepare for future threats”, said Dr Richard Hatchett, CEO of CEPI.  “In just three months, cases of Bundibugyo have spread rapidly across the DRC, making this the largest and deadliest outbreak the country has ever faced. We are proud to support Minapharm’s Bundibugyo vaccine candidate: it will round out CEPI’s portfolio, give the world another shot on goal, and advance Minapharm’s proprietary MVA platform, which if successful can serve as the basis for future African-manufactured filovirus vaccines. The faster we can advance a pipeline of promising candidates, the better our chances of saving lives and bringing this epidemic under control.”

    CEPI’s goal is to bring at least two Bundibugyo vaccines to Emergency Use Authorisation and WHO Prequalification to respond to this outbreak, while also building readiness for future Bundibugyo epidemics.

    Dr. Wafik Bardissi, Group Chairman and CEO of Minapharm and Chairman of ProBioGen, said: “For more than 25 years, Minapharm has built proven biologics capabilities in Egypt and, together with ProBioGen, established a cross-continental group model combining scientific innovation, proprietary technologies and advanced biomanufacturing.”

    Dr. Bardissi added: “This programme demonstrates the strength of our capabilities across the full biologics continuum, from design and development through to manufacturing, in response to an urgent public-health threat. With CEPI’s support, we are turning scientific ingenuity into health sovereignty, drawing on the breadth of our technologies and know-how to advance a vaccine response for Africa.”

    “ProBioGen’s MVA-CR19 platform was developed to enable rapid generation of recombinant MVA vaccine candidates and scalable manufacturing,” said Dr Volker Sandig, Chief Scientific Officer of ProBioGen. “We are proud to bring this platform and our CMC expertise to a Minapharm-led programme supported by CEPI, helping advance a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation in response to an urgent public-health need.”

    Dr Jean Kaseya, Director General, Africa CDC, said, “Bundibugyo virus is now driving the largest Ebola outbreak DRC has ever faced. A vaccine candidate advanced by an African company is exactly the kind of capability our continent needs – not just for this outbreak, but so that Africa can develop and manufacture the tools it needs to protect its own people. We welcome CEPI’s support for Minapharm’s work as a concrete step toward that health sovereignty.”

    To develop the Bundibugyo-specific vaccine candidate, ProBioGen —a wholly-owned subsidiary of Minapharm based in Germany—will generate the recombinant MVA drug substance under Good Manufacturing Practice (GMP) guidelines. The drug substance is the active component of a vaccine which includes viral proteins that could train the immune system to recognise and fight a specific pathogen – in this case, Bundibugyo ebolavirus. The drug substance will then be shipped to Minapharm’s facility in Cairo, Egypt, to create the drug product – the finished vaccine mixture which combines the drug substance with other vaccine ingredients and packaging ready for testing. In parallel, Minapharm plans to transfer drug substance manufacturing to its biotechnology facilities in Cairo, enabling fully local drug substance and drug product manufacturing.

    The project leverages more than 25 years of Minapharm’s proven track record and experience in the development, end-to-end manufacturing and commercialisation of complex biologics in Africa.

    If the Phase 1 trial of the vaccine candidate is successful, CEPI anticipates working with Minapharm and ProBioGen to support late-stage trials to generate efficacy data for emergency use authorisation and licensure. CEPI, Minapharm and ProBioGen are committed to enabling rapid, affordable supply of the vaccine to affected countries and to the populations that need them should it prove safe and effective.

    A positive outcome from this project could also lay the foundation for the future expansion of Minapharm’s vaccine manufacturing capabilities, potentially with support from CEPI and other partners.

    To date, CEPI’s Bundibugyo virus vaccine development programme receives funds from the European Commission through its 2026 grant under Horizon Europe to CEPI, the U.S. Department of State and CEPI’s existing core funding.

    Notes to Editors

    CEPI’s funding was awarded to Minapharm for its Bundibugyo vaccine project following its application to CEPI’s Call for Proposals seeking vaccine developers to advance the development of Bundibugyo vaccine candidates.

    MVA-C19 platform

    MVA-CR19 is ProBioGen’s proprietary modified vaccinia Ankara (MVA) vaccine platform. MVA is a highly attenuated poxvirus vector that is replication-deficient in human cells: it can enter cells and express the vaccine antigens it carries, but cannot multiply or spread. ProBioGen’s platform combines the MVA-CR19 strain with its AGE1 production cell line platform and TetherexX™ recombination technology to support rapid recombinant MVA generation and scalable manufacturing.

    The MVA platform holds potential as it has a well-established safety profile in people. Alongside studies demonstrating long-lasting immunity in people vaccinated with MVA-based mpox and Zaire ebolavirus vaccines, positive data has also been obtained in preclinical studies of MVA vaccines targeting Sudan ebolavirus, Marburg virus and other infectious diseases. The technology was also safe for use in immunosuppressed individuals and people living with HIV vaccinated with MVA-based vaccines targeting other diseases.

    CEPI’s response to the Bundibugyo ebolavirus outbreak

    *CEPI has worked around the clock with its partners to respond to the Bundibugyo outbreak, announcing its first Bundibugyo vaccine development partnerships just two weeks after the declaration of the outbreak in mid-May. CEPI has to date already invested in Bundibugyo vaccines being developed using mRNA (Moderna), ChAdOx (the University of Oxford/ Serum Institute of India) and rVSV (IAVI with manufacturing by Hilleman Laboratories, and Public Health Vaccines) technologies. 

    To accelerate outbreak response efforts, CEPI has also activated its global networks of laboratories, manufacturers and clinical trial partners, is supporting a clinical trial to evaluate potential treatments and engaging regulators to align on vaccine approval pathways. In parallel, CEPI is working with partners including affected countries, Gavi, Africa CDC, WHO, UNICEF, the World Bank and development finance institutions so the downstream conditions needed to enable equitable access—including procurement, allocation and deployment—are put in place.

    About CEPI

    CEPI is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Central to CEPI’s pandemic-beating plan is the ’100 Days Mission’ to develop safe, effective and accessible vaccines against new threats in just 100 days. CEPI is seeking $2.5 billion to execute CEPI 3.0, its 2027-2031 strategy which will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Learn more at CEPI.net.

    About Minapharm

    Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the largest biopharmaceutical company in Africa, with over 25 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, the Group develops, manufactures and commercializes a broad portfolio spanning complex small molecules, recombinant proteins, and monoclonal antibodies, supported by an extensive pipeline of genetically engineered medicines and cell and gene therapies. Minapharm operates seven manufacturing facilities and commercializes more than 100 life-saving and life-enhancing products. Its two biotechnology facilities in Cairo are the region’s longest-established end-to-end drug substance and drug product operations, from cell line to finished vial. Together with its wholly owned Berlin-based subsidiary, ProBioGen AG, Minapharm has built an integrated biopharmaceutical model spanning research, proprietary technology, development and manufacturing. Through its subsidiary, ProBioGen, the Group is a global provider of proprietary technologies for vaccines, complex proteins, and cell and gene therapies, which have contributed to multiple FDA-approved products. Minapharm employs a combined workforce of more than 1,700 people and is listed on the Egyptian Exchange (EGX: MIPH). Learn more at minapharm.com 

    About ProBioGen

    ProBioGen is a Berlin-based expert in the development and manufacturing of biopharmaceuticals, viral vectors, and vaccines, powered by proprietary technologies that enhance product quality and features. It has developed multiple innovative vaccine platforms, including Lenti.RiGHT®, AGE1 host cell lines and the IP-protected MVA-CR19 strain, which has a unique genomic signature. Operating for over 30 years, ProBioGen runs three manufacturing lines in Berlin, where 300 employees contribute to advancing next-generation therapies and global biotech innovation. For more information about ProBioGen, follow us on LinkedIn.

    Photo – https://mma.prnewswire.com/media/3008898/Minapharm_CEPI.jpg

     

    Cision View original content:https://www.prnewswire.co.uk/news-releases/african-bundibugyo-ebolavirus-vaccine-candidate-to-be-advanced-to-clinical-trials-302861775.html

    Related Posts

    WHO Bahrain and RCSI Medical University of Bahrain sign agreement to strengthen health workforce education, research and community engagement

    November 15, 2026

    Innovative Immunology Biotech Windward Bio Lists on Nasdaq

    November 14, 2026

    Alwaleed Philanthropies and The Research, Development and Innovation Authority Sign Strategic Partnership valued at SAR 10 million to Advance Innovation and Technology Solutions

    November 13, 2026

    GHA Honors The Second Affiliated Hospital Zhejiang University School of Medicine with Distinction for Excellence in International Medical Travel Patient Experience

    November 13, 2026

    81% of Software Teams Have Merged AI-Written Code They Didn’t Fully Understand, Finds TestMu AI’s State of AI in Quality Engineering 2026 Report

    November 13, 2026

    Korea Nakajo Accelerates Overseas Expansion with Commitment to Quality and Environmental Management

    November 13, 2026
    Latest News

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    Three nations launch carbon crediting initiative at COP31

    November 13, 2026
    © 2026 GCC Tabloid | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.